Joel A. Krauser

1.0k total citations
26 papers, 854 citations indexed

About

Joel A. Krauser is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Joel A. Krauser has authored 26 papers receiving a total of 854 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Pharmacology and 8 papers in Oncology. Recurrent topics in Joel A. Krauser's work include Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (5 papers) and RNA Interference and Gene Delivery (4 papers). Joel A. Krauser is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (5 papers) and RNA Interference and Gene Delivery (4 papers). Joel A. Krauser collaborates with scholars based in United States, Switzerland and France. Joel A. Krauser's co-authors include F. Peter Guengerich, William W. Johnson, Piet Swart, Jeffrey A. Clark, Sophie Schmitt, Laurent Meijer, F. Peter Guengerich, François Natt, Jürg Hunziker and Esther van de Kerkhof and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Biochemistry.

In The Last Decade

Joel A. Krauser

26 papers receiving 835 citations

Peers

Countries citing papers authored by Joel A. Krauser

Since Specialization

Citations

This map shows the geographic impact of Joel A. Krauser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel A. Krauser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel A. Krauser more than expected).

Fields of papers citing papers by Joel A. Krauser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel A. Krauser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel A. Krauser. The network helps show where Joel A. Krauser may publish in the future.

Co-authorship network of co-authors of Joel A. Krauser

This figure shows the co-authorship network connecting the top 25 collaborators of Joel A. Krauser. A scholar is included among the top collaborators of Joel A. Krauser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel A. Krauser. Joel A. Krauser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MO469: GPR124—A Driver of Fibrotic Kidney Diseases 2022 ·Nephrology Dialysis Transplantation ·(unknown), Antje Schmidt, (unknown), Yan Liu, (unknown), Hendrik Urbanke, Franz Dürrenberger, Joel A. Krauser, Philipp Skroblin, (unknown), (unknown), Christian M. Stegmann, Uwe Andag	1
2	MS565: A SPECT Tracer for Evaluating the Brain Penetration of BAF312 (Siponimod) 2015 ·ChemMedChem ·Emmanuelle Briard, Bettina Rudolph, Sandrine Desrayaud, Joel A. Krauser, Yves P. Auberson	17
3	Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite 2014 ·Xenobiotica ·Joel A. Krauser, Yi Jin, Markus Walles, Ulrike Pfaar, James Sutton, Marion Wiesmann, Daniel Graf, (unknown), (unknown), Gian Camenisch, Piet Swart	29
4	Biodistribution and Metabolism Studies of Lipid Nanoparticle–Formulated Internally [3H]-Labeled siRNA in Mice 2014 ·Drug Metabolism and Disposition ·(unknown), (unknown), Thomas Faller, Esther van de Kerkhof, François Natt, Jürg Hunziker, (unknown), Iwan Beuvink, Keith Bowman, Jeremy L. Baryza, (unknown), Chandra Vargeese, Olivier Heudi, Markus Stoeckli, Joel A. Krauser, Piet Swart	43
5	Application of a Deuterium Replacement Strategy to Modulate the Pharmacokinetics of 7-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-3-(4-methoxy-2-methylphenyl)-2,6-dimethylpyrazolo[5,1-b]oxazole, a Novel CRF1 Antagonist 2014 ·Drug Metabolism and Disposition ·Rowan Stringer, Gareth Williams, Franck Picard, Bindi Sohal, Olivier Kretz, (unknown), Joel A. Krauser	18
6	Metabolism and Disposition of the Metabotropic Glutamate Receptor 5 Antagonist (mGluR5) Mavoglurant (AFQ056) in Healthy Subjects 2013 ·Drug Metabolism and Disposition ·Markus Walles, (unknown), Yi Jin, M. RITZAU, Luc Alexis Leuthold, Joel A. Krauser, Hans-Peter Gschwind, David A. Carcache, Matthias Kittelmann, (unknown), Mike Ufer, Ralph Woessner, Abhijit Chakraborty, Piet Swart	23
7	Metabolism Studies of Unformulated Internally [3H]-Labeled Short Interfering RNAs in Mice 2013 ·Drug Metabolism and Disposition ·(unknown), (unknown), Thomas Faller, Esther van de Kerkhof, François Natt, Jürg Hunziker, Joel A. Krauser, Piet Swart	42
8	A Unique Automation Platform for Measuring Low Level Radioactivity in Metabolite Identification Studies 2012 ·PLoS ONE ·Joel A. Krauser, Markus Walles, (unknown), Daniel Graf, Piet Swart	2
9	Tritium labeling of full‐length small interfering RNAs 2012 ·Journal of Labelled Compounds and Radiopharmaceuticals ·(unknown), François Natt, Jürg Hunziker, Joel A. Krauser, Hendrik Andres, Piet Swart	13
10	Metal complexes of modified cyclen as catalysts for hydrolytic restriction of plasmid DNA 2010 ·Journal of Inorganic Biochemistry ·Joel A. Krauser, (unknown), (unknown)	10
11	Cytochrome P450 3A4-catalyzed Testosterone 6β-Hydroxylation Stereochemistry, Kinetic Deuterium Isotope Effects, and Rate-limiting Steps 2005 ·Journal of Biological Chemistry ·Joel A. Krauser, F. Peter Guengerich	76
12	Testosterone 1β‐hydroxylation by human cytochrome P450 3A4 2004 ·European Journal of Biochemistry ·Joel A. Krauser, Markus Voehler, Li‐Hong Tseng, Alexandre B. Schefer, Markus Godejohann, F. Peter Guengerich	50
13	Aryl Hydrocarbon Receptor Activation and Cytochrome P450 1A Induction by the Mitogen-Activated Protein Kinase Inhibitor U0126 in Hepatocytes 2004 ·Molecular Pharmacology ·Lise O. Andrieux, Sophie Langouët, Alain Fautrel, Frédéric Ezan, Joel A. Krauser, (unknown), F. Peter Guengerich, Georges Baffet, André Guillouzo	67
14	Generation of New Protein Kinase Inhibitors Utilizing Cytochrome P450 Mutant Enzymes for Indigoid Synthesis 2004 ·Journal of Medicinal Chemistry ·F. Peter Guengerich, (unknown), Sophie Schmitt, Joel A. Krauser, (unknown), Laurent Meijer	64
15	Inhibition of Arginine Gingipains (RgpB and HRgpA) with Benzamidine Inhibitors: Zinc Increases Inhibitory Potency 2002 ·Biological Chemistry ·Joel A. Krauser, Jan Potempa, James Travis, James C. Powers	15
16	Microsomal Oxidation of Tribromoethylene and Reactions of Tribromoethylene Oxide 2002 ·Chemical Research in Toxicology ·Tadao Yoshioka, Joel A. Krauser, F. Peter Guengerich	5
17	Tetrachloroethylene Oxide: Hydrolytic Products and Reactions with Phosphate and Lysine 2002 ·Chemical Research in Toxicology ·Tadao Yoshioka, Joel A. Krauser, F. Peter Guengerich	12
18	Diversity in Mechanisms of Substrate Oxidation by Cytochrome P450 2D6 2001 ·Journal of Biological Chemistry ·Imad Hanna, Joel A. Krauser, Hongliang Cai, Misook Kim, F. Peter Guengerich	36
19	On assignment of fundamental vibrational modes of hypophosphite anion and its deuterated analogue 1996 ·Vibrational Spectroscopy ·Ruifeng Liu, (unknown), (unknown), Jeffrey A. Clark, Joel A. Krauser, (unknown)	8
20	Density Functional Theory Study of Molecular Structures and Vibrational Spectra of 3,4- and 2,3-Pyridyne 1996 ·The Journal of Physical Chemistry ·Ruifeng Liu, (unknown), Jeffrey A. Clark, (unknown), (unknown), Joel A. Krauser	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact